Brands:: Shire , Takeda


• Replacement therapy in primary immunodeficiency
• Replacement therapy in secondary immunodeficiency due to myeloma or chronic lymphocytic leukaemia
• Replacement therapy in childn w/ congenital AIDS & recurrent infections
• Idiopathic thrombocytopenic purpura in childn or adult at high risk of bleeding or pre-op to correct platelet count
• Allogeneic bone marrow transplantation: Treatment of infections & prophylaxis of graft versus host disease



Shire is known as one of the world’s fastest growing specialty pharmaceutical companies. Today, it has value around US $5billion and is the third largest pharma company in the UK. It is the market leader in attention deficit and hyperactivity disorder (ADHD) in the United States, as well as having a growing European network and an exciting set of products being developed for launch and marketing in the future. But only 27 years ago was it a tiny business above a shop. How did it become so successful?


For more than 230 years, Takeda has brought hope to people around the world through our people-centered and innovation-driven approach to science and medicine. As a global pharmaceutical leader, we focus on solving unmet needs where we can make a real difference—and on putting patients first. Our therapeutics focus is oncology, gastroenterology, and the central nervous system, as well as vaccines.
SKU: BIOBL011 Categories: , Tag:
You've just added this product to the cart: